Frank McGrew, MD
Cardiovascular Disease · Memphis, TNNPI 1922190396
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 19.9%. Reporting peaked in 2019 at $38,310 and has fallen 65.0% since, to $13,423 in 2025. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,237 payments — averaging $96.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$24K
- Novartis$17K
- AstraZeneca$12K
- Bayer$12K
- Boehringer Ingelheim$9K
- Lilly USA, LLC$8K
- plus $37K from 50 others
Across 665 payments — averaging $3021.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$421K
- Novo Nordisk AS$385K
- CSL Behring$372K
- Novartis$355K
- Cvrx, Inc.$89K
- Medtronic$87K
- plus $300K from 13 others
What the payments were for
- Consulting fees$20,93518%
- Speaking & faculty fees$63,35953%
- Travel & lodging$5,8085%
- Food & beverage$28,39824%
- Education$6751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$17,411
- JARDIANCE$14,554
- FARXIGA$10,700
- Kerendia$9,992
- ENTRESTO$8,820
- XARELTO$7,200
- LEQVIO$5,604
- LifeVest$3,750
- ELIQUIS$2,525
- Sotalol Hydrochloride$1,100
- Micra$1,082
- OPTIMIZER$1,004
- Barostim Neo System$471
- AURORA EV-ICD MRI SURESCAN$344
- TherOx DS2 Console$287
- Catheter$287
- Downstream Cartridge$287
- Repatha$246
- Confirm Rx$222
- PNEUMOVAX 23$150
How this compares
$119,176 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 41 | $1,329,346 |
| WainuaEplontersen Sodium | 15 | $599,194 |
| EliquisApixaban | 586 | $537,949 |
| EntrestoSacubitril/Valsartan | 417 | $401,160 |
| Repatha SureclickEvolocumab | 382 | $338,140 |
| Orenitram ErTreprostinil Diolamine | 11 | $316,566 |
| OzempicSemaglutide | 216 | $228,999 |
| XareltoRivaroxaban | 185 | $201,326 |
| LetairisAmbrisentan | 11 | $143,508 |
| JardianceEmpagliflozin | 148 | $140,500 |
| FarxigaDapagliflozin Propanediol | 156 | $119,992 |
| VascepaIcosapent Ethyl | 158 | $91,152 |
| MultaqDronedarone Hcl | 46 | $71,658 |
| KerendiaFinerenone | 66 | $53,412 |
| NexletolBempedoic Acid | 113 | $51,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $3,325 | $1,867,295627 claims |
| AstraZenecaWainua, Farxiga, Brilinta | $12,341 | $733,940192 claims |
| NovartisEntresto | $17,476 | $401,160417 claims |
| Novo NordiskOzempic, Wegovy | $883 | $258,362236 claims |
| Johnson & JohnsonXarelto | $7,935 | $201,326185 claims |
| Boehringer IngelheimJardiance, Pradaxa | $8,759 | $146,296173 claims |
| Sanofi-aventis U.S. LLCMultaq | $333 | $71,65846 claims |
| BayerKerendia | $11,734 | $53,41266 claims |
| Esperion Therapeutics, Inc.Nexletol | $184 | $51,961113 claims |
| Lilly USA, LLCMounjaro | $8,054 | $50,15148 claims |
| MerckVerquvo | $1,025 | $29,08942 claims |
| AmgenCorlanor | $2,414 | $9,54412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Memphis
- Steven GubinMemphis$248K
- Ritin BombMemphis$16K
- Arie SzatkowskiMemphis$13K
- William AitkenMemphis$12K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Andrew ZurickNashville$231K
- Mark ZenkerNashville$225K
- Selcuk TombulChattanooga$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.